Back to top
more

DexCom (DXCM)

(Delayed Data from NSDQ)

$128.37 USD

128.37
1,778,973

+1.72 (1.36%)

Updated May 3, 2024 04:00 PM ET

After-Market: $128.34 -0.03 (-0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (150 out of 252)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Here's Why You Should Retain CVS Health (CVS) Stock for Now

Investors are optimistic about CVS Health (CVS) on its strong segmental performance and impressive restructuring plan.

Henry Schein (HSIC) Sales Hurt by Cyber Attack, Macro Woes

Henry Schein's (HSIC) financial operations are being affected by the current macroeconomic environment.

Orthofix (OFIX) Releases New Data for Spinal Fusion Procedures

According to Orthofix (OFIX), this data highlights the noninvasive and cost-effective nature of SpinalStim, enabling patients to continue their healing in the comfort of their homes.

Here's Why Investors Should Retain Bruker (BRKR) Stock Now

Investors remain optimistic about Bruker (BRKR) due to the strength of the BSI BioSpin and CALID groups.

5 MedTech Stocks Poised to Continue Their Winning Streaks in 2024

Stocks like DexCom Inc. (DXCM), Integer Holdings (ITGR), Penumbra (PEN), Haemonetics (HAE), Health Equity (HAE) and are likely to continue their strong performance in 2024.

Three Reasons to Add DaVita (DVA) Stock to Your Portfolio

DaVita's (DVA) strength in its DaVita Kidney Care raises optimism about the stock.

Sanghamitra Saha headshot

Play Potential Earnings Beat With 5 Top-Ranked Stocks

These top-ranked stocks are likely to beat on the bottom line in their upcoming releases. Tap Amazon.com (AMZN), Deckers Outdoor (DECK), Wingstop (WING), DexCom (DXCM) and NVIDIA (NVDA).

Thermo Fisher (TMO) Unveils CorEvitas Pharmacovigilance Platform

Thermo Fisher (TMO) introduces the CorEvitas pharmacovigilance platform for clinical research registries.

DexCom (DXCM) Stock Falls Amid Market Uptick: What Investors Need to Know

In the closing of the recent trading day, DexCom (DXCM) stood at $122.17, denoting a -0.51% change from the preceding trading day.

3 Reasons Why Growth Investors Shouldn't Overlook DexCom (DXCM)

DexCom (DXCM) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Penumbra (PEN) Stock Up 16.2% YTD: Will the Rally Continue?

Investors are optimistic about Penumbra (PEN), driven by growth in the vascular segments and upbeat guidance.

Thermo Fisher's (TMO) PPD Business Backs BARDA's Clinical Trial

Thermo Fisher's (TMO) PPD clinical research business is selected by BARDA to support the Phase II platform clinical trial to treat ARDS.

Universal Health (UHS) Up 17% in 3 Months: More Growth Ahead?

Universal Health (UHS) is well-poised for growth on the back of the resumption of elective procedures, acquisitions and solid operating cash flows.

Henry Schein (HSIC) Enters Orthopedic Market With New Buyout

Henry Schein's (HSIC) recent deals will position it as a prominent producer and supplier in the orthopedic market's Foot and Ankle, Hand and Wrist extremity sectors.

Exact Sciences' (EXAS) Solid Cologuard Sales, Innovation Aid

Following the acquisitions of Paradigm and Ashion, Exact Sciences (EXAS) is offering therapy selection tests for patients with advanced cancer.

Myriad Genetics' (MYGN) New Platform to Advance Cancer Care

Myriad Genetics' (MYGN) new MCRR platform advances patient care by combining structured clinical data with genetic and genomic results.

Bruker (BRKR) Installs First 1.2 GHz NMR at Ohio University

Bruker (BRKR) 1.2 GHz AVANCE NMR spectrometer is cutting-edge equipment capable of performing high-resolution liquid and solid-state NMR studies.

Bio-Rad (BIO) Faces Soft Industry-wide Demand, Macro Woes

Bio-Rad's (BIO) margin performance suffers due to elevated raw material costs, increased logistics costs and higher employee-related expenses.

3 Reasons to Add HealthEquity (HQY) Stock to Your Portfolio

HealthEquity's (HQY) strength in HSA raises optimism about the stock.

Venus Concept (VERO) Expands Global Reach With New Partnerships

Venus Concept (VERO) expects its deals to fetch continued success in both the United Kingdom and India.

Quest Diagnostics (DGX) Unveils the 88-Compound NPS Test Panel

Quest Diagnostics (DGX) launches the new 88-Compound NPS test panel to address the changing drug epidemic.

DexCom's (DXCM) G7 CGM Connects With Tandem's Insulin Pump

Dexcom's (DXCM) G7 integrates with Tandem's t:slim X2, revolutionizing diabetes care. A perfect combination of accuracy and innovation, this synergy sets a new standard in continuous glucose monitoring.

Masimo's (MASI) Stork Baby Monitoring System Approved by FDA

The latest FDA clearance of Masimo's (MASI) Stork smart home baby monitoring system is likely to provide a continuous and accurate view of babies' health data.

Here's Why You Should Invest in Penumbra (PEN) Stock Now

Investors are optimistic about Penumbra (PEN), which is led by growth in vascular and neuro businesses.